Ralf Amann

Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

In Vitro Antiviral Properties of Two Recombinant Sendai Virus Vectors Encoding ORFV 011 and ORFV 059 Genes.

In Vitro Antiviral Properties of Two Recombinant Sendai Virus Vectors Encoding ORFV 011 and ORFV 059 Genes.

Journal: Viruses
Published: March 24, 2026

Broadening SARS-CoV-2 Immunity by Combining ORFV and Protein-Based Vaccines.

Broadening SARS-CoV-2 Immunity by Combining ORFV and Protein-Based Vaccines.

Journal: Vaccines
Published: November 19, 2025

Heterologous ORFV-Ad26 vaccination broadens antibody breadth and amplifies cellular immunity against SARS-CoV-2 spike.

Heterologous ORFV-Ad26 vaccination broadens antibody breadth and amplifies cellular immunity against SARS-CoV-2 spike.

Journal: Frontiers in immunology
Published: September 29, 2025

Heterologous prime-boost vaccination with VLA2001 and an ORFV-based vector enhances spike- and nucleocapsid-specific immunity in mice.

Heterologous prime-boost vaccination with VLA2001 and an ORFV-based vector enhances spike- and nucleocapsid-specific immunity in mice.

Journal: Frontiers in immunology
Published: July 29, 2025

Commentary on 'Confounding Variable in Recent Clinical Trial on ORFV-Based Therapeutics'.

Commentary on 'Confounding Variable in Recent Clinical Trial on ORFV-Based Therapeutics'.

Journal: Reviews in medical virology
Published: June 04, 2025

Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8+ T cell responses.

Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8+ T cell responses.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 13, 2025

Advancing ORFV-Based Therapeutics to the Clinical Stage.

Advancing ORFV-Based Therapeutics to the Clinical Stage.

Journal: Reviews in medical virology
Published: March 06, 2025

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.

Journal: Human vaccines & immunotherapeutics
Published: October 14, 2024

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster.

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster.

Journal: Vaccines
Published: October 02, 2024

Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats.

Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats.

Journal: Vaccines
Published: March 27, 2024

Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2.

Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2.

Journal: Vaccines
Published: March 25, 2024

Efficient and scalable clarification of Orf virus from HEK suspension for vaccine development.

Efficient and scalable clarification of Orf virus from HEK suspension for vaccine development.

Journal: Vaccine: X
Published: November 29, 2023
Showing 1-12 of 29

Last Updated: 09/26/2026